You are here: Industry Insights > Merck

News List

Merck Awarded its first CRISPR Patent pharmaasia
June 26, 2017
Patent covers successful integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR.
Merck Ventures creates new immuno-oncology company iOnctura cphi-online
June 23, 2017
iOnctura is set up to develop a pipeline of assets targeting immunosuppression in the tumour microenvironment.
F-star expands its relationship with Merck pharmaasia
June 19, 2017
New strategic collaboration to develop and commercialise five bispecific immuno-oncology antibodies, including F-star’s lead asset FS118.
Merck Provides Update on Multiple Myeloma Studies of KEYTRUDA® in Combination with Other Therapies americanpharmaceuticalreview
June 14, 2017
Merck has provided an update on two combination studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. Merck has accepted the external Data Monitoring Committee recommendation to pause new enrollment o
Response to Merck's Ebola vaccine lasts at least a year, study finds fiercepharma
June 14, 2017
In a phase 3 trial in West Africa, Merck’s Ebola vaccine rVSV-ZEBOV has already shown it can elicit a quick immune response. Now, a new study in the U.S. found that the vaccine's protective qualities can last for at least a year.
Interview – German Merck doubles down on dual-acting cancer agents epvantage
June 13, 2017
Pfizer andnclick=getInfo('1042'); return false;Merck KGaAsuccessfully got thenclick=storyWordlink('PD-L1'
Interview – German Merck doubles down on dual-acting cancer agents epvantage
June 13, 2017
German Merck doubles down on dual-acting cancer agents
Anyone can become more curious. Is that true? worldpharmanews
June 01, 2017
Merck, a leading science and technology company, today announced the start of an experiment entitled "Anyone can become more curious".
Merck's experimental Ebola vaccine poised for emergency use in Congo outbreak fiercepharma
June 01, 2017
The Democratic Republic of the Congo has given initial approval for the emergency use of Merck’s as-yet-unlicensed Ebola shot to combat a local outbreak, and medical providers are putting together plans for administering it.
Merck opens first joint Bioprocess Scale-up Lab pharmaasia
June 01, 2017
Merck opens joint Bioprocess Scale-up Lab in collaboration with Stelis Biopharma in India.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page